Summary
ATRO Medical developed a revolutionary prothesis that quickly relieves pain and restores mobility for severe KOA patients with a dysfunctional lateral meniscus: Trammpolin. We offer a minimally invasive, low impact procedure that postpones undesirable TKR and reduces KOA-related healthcare costs and medication dependency, while restoring full knee functioning. Our innovation is composed of a dual highly biocompatible polymer that carries the body weight and is uniquely shaped to reproduce the anatomical shape and mechanical properties of the native meniscus. The technology has proven itself for the medial meniscus and received the Breakthrough Device Designation of the US FDA in 2020. For successful market entry of our lateral Trammpolin in 2026, we aim to finalize our pre-clinical activities, conduct a FIH-study, and obtain CE-marking. In parallel we will perform a health economics analysis as a crucial step towards obtaining reimbursement for large scale uptake in the medical system.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/190115658 |
| Start date: | 01-04-2023 |
| End date: | 30-09-2025 |
| Total budget - Public funding: | 3 570 575,00 Euro - 2 499 402,00 Euro |
Cordis data
Original description
ATRO Medical developed a revolutionary prothesis that quickly relieves pain and restores mobility for severe KOA patients with a dysfunctional lateral meniscus: Trammpolin. We offer a minimally invasive, low impact procedure that postpones undesirable TKR and reduces KOA-related healthcare costs and medication dependency, while restoring full knee functioning. Our innovation is composed of a dual highly biocompatible polymer that carries the body weight and is uniquely shaped to reproduce the anatomical shape and mechanical properties of the native meniscus. The technology has proven itself for the medial meniscus and received the Breakthrough Device Designation of the US FDA in 2020. For successful market entry of our lateral Trammpolin in 2026, we aim to finalize our pre-clinical activities, conduct a FIH-study, and obtain CE-marking. In parallel we will perform a health economics analysis as a crucial step towards obtaining reimbursement for large scale uptake in the medical system.Status
SIGNEDCall topic
HORIZON-EIC-2022-ACCELERATOROPEN-01Update Date
31-07-2023
Images
No images available.
Geographical location(s)
